|
|
| | AVN-101 Basic information |
| Product Name: | AVN-101 | | Synonyms: | 1H-Pyrido[4,3-b]indole, 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-phenylethyl)-, hydrochloride (1:1);AVN-101 1061354-48-0;2,8-dimethyl-5-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride;AVN-101 HCl;AVN-101, 10 mM in DMSO | | CAS: | 1061354-48-0 | | MF: | C21H24N2*ClH | | MW: | 340.9 | | EINECS: | | | Product Categories: | APIS | | Mol File: | 1061354-48-0.mol |  |
| | AVN-101 Chemical Properties |
| solubility | DMF: 10 mg/ml
DMSO: 5 mg/ml
Ethanol: 1 mg/ml | | form | Solid | | color | White to light yellow |
| | AVN-101 Usage And Synthesis |
| Uses | AVN-101 hydrochloride is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (Ki of 153 pM), with slightly lesser potency toward 5-HT6, 5-HT2A, and 5HT-2C receptors (Ki values of 2.04 nM, 1.56 nM, and 1.17 nM, respectively). AVN-101 hydrochloride also exhibits a rather high affinity toward histamine H1 (Ki of 0.58 nM) and adrenergic α2A, α2B, and α2C (Ki= 0.41-3.6 nM) receptors. AVN-101 hydrochloride can be studied in such diseases as general anxiety disorders, depression, schizophrenia, and multiple sclerosis[1]. | | IC 50 | 5-HT7 Receptor: 0.153 nM (Ki); 5-HT2C Receptor: 1.17 nM (Ki); 5-HT2A Receptor: 1.56 nM (Ki); 5-HT6 Receptor: 2.04 nM (Ki); 5-HT2B Receptor: 10.6 nM (Ki); 5-HT1A Receptor: 61 nM (Ki); 5-HT1B Receptor: 720 nM (Ki); H1 Receptor: 0.58 nM (Ki); Alpha-2B adrenergic receptor: 0.41 nM (Ki); Alpha-2A adrenergic receptor: 1.77 nM (Ki); Alpha-2C adrenergic receptor: 3.55 nM (Ki); Alpha-1B adrenergic receptor: 9.4 nM (Ki); Alpha-1A adrenergic receptor: 18.9 nM (Ki); Alpha-1D adrenergic receptor: 30.2 nM (Ki) | | References | [1] Alexandre V Ivachtchenko, et al. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620. DOI:10.3233/JAD-151146 |
| | AVN-101 Preparation Products And Raw materials |
|